Faculty Collaboration Database

Vaccines and use of immunosuppressive and immunomodulatory therapy in a pediatric dermatology clinic-A single institution experience. Pediatr Dermatol 2023;40(4):644-646

Date

06/16/2023

Pubmed ID

37321854

DOI

10.1111/pde.15352

Scopus ID

2-s2.0-85161896057 (requires institutional sign-in at Scopus site)

Abstract

Vaccine type and timing are critical issues to prevent unintended infections in those on immunosuppressive therapies. We retrospectively chart reviewed patients at Children's Wisconsin Pediatric Dermatology Clinic on immunosuppressives and immunomodulators between 11/1/2012 and 6/1/2020 and found that approximately 76% of patient encounters do not have documented vaccine counseling in the medical chart before initiation of immunosuppressives and immunomodulators. As age increased, vaccine counseling was less likely to be documented (odds ratio: 0.89; 95% confidence interval: 0.84-0.95, p = .001). In addition, 13 patient encounters (4%) were not up to date with live vaccines before immunosuppressive or immunomodulating therapy. There is an opportunity to improve clinical processes to ensure documentation of vaccination status and vaccine counseling before starting immunosuppressive and immunomodulator medications in a pediatric dermatology clinic.

Author List

Tran J, Trinh DL, Pan AY, Humphrey SR

Authors

Stephen R. Humphrey MD Associate Professor in the Dermatology department at Medical College of Wisconsin
Amy Y. Pan PhD Associate Professor in the Pediatrics department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Child
Dermatology
Humans
Immunomodulation
Immunosuppressive Agents
Retrospective Studies
Vaccination
Vaccines